Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong...

Novonesis delivers strong half-year results and increases full-year outlook In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic...

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA...

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for...